Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Frontera London

- PMLiVE

World Heart Day highlights actions to prevent and control cardiovascular disease

CVD is the world’s leading cause of death, resulting in 18.6 million global deaths each year

- PMLiVE

Shionogi’s antiviral COVID-19 treatment meets phase 3 primary endpoint

Ensitrelvir reduced the time taken to resolve five key symptoms

- PMLiVE

Biogen and Eisai’s lecanemab shows promise in confirmatory Alzheimer’s study

Results from the phase 3 trial showed reduction in clinical decline

5 Healthcare Marketing Blunders | How To Avoid Them.

5 Healthcare Marketing Blunders | How To Avoid Them.

Here are 5 healthcare marketing blunders and how best to avoid them.

The Good Ideas Group

Design Trends of 2022 and Beyond!

Design Trends We’ve Seen In 2022

Our graphic designer Isla takes a deep dive into the graphic design trends we’ve seen in 2022 and what to expect throughout 2023 and beyond.

The Good Ideas Group

- PMLiVE

Rare diseases: making a difference through education

Medscape Education team up with The Guardian to launch a Rare Disease campaign in the UK.

Medscape Education

Biogen Idec building

Biogen to pay $900m to settle whistleblower’s MS drug kickback lawsuit

For pursuing the case, the former employee will receive about $250m

- PMLiVE

WHO reports warnings of ‘COVID-19 complacency’ from countries tracking global vaccine roll-out

Vaccination rates in low-income countries stand at 19% compared to almost 75% in high-income countries

- PMLiVE

Genentech and ArsenalBio join to identify successful T-cell oncology therapies

While CAR-T therapy has shown promise in blood cancers, solid tumours present additional challenges

- PMLiVE

Janssen’s Erleada combination accepted in Scotland for prostate cancer

The combination therapy significantly improved progression-free and overall survival rates

- PMLiVE

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment

Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?

Say Communications

Value is in the eye of the customer. Co-creation is a bridge to value.

We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning.  Our interviews reveal important insights about the tensions between...

nzyme

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links